DOSSIER · 13F-HR · Q2 2026

Boxer Capital Management, LLC

$1.3B in tracked AUM across 63 positions as of Q2 2026.

BC
CIK 0002018299 · last filed Jun 30, 2026
Total AUM
$1.3B
as of Q2 2026
Holdings
63
positions
Whale Score
70
70
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Boxer Capital Management LLC 13F Filing
Portfolio Overview

Boxer Capital Management LLC manages a concentrated, high-conviction portfolio totaling approximately $266.73 million as of September 30, 2025. The firm has executed a significant strategic pivot over the quarter, evidenced by a 34.3% increase in total portfolio value (rising from $198.66 million) and a substantial turnover in holdings. The portfolio consists of only 26 positions, indicating a ...

Key Holdings

The portfolio is characterized by a "bar-bell" structure, with massive exposure to a few top names and a long tail of smaller positions.

  • Top-Tier Dominance: The two largest positions, Tango Therapeutics Inc (TNGX) and uniQure N.V (QURE), command a combined 48.28% of the total portfolio value. Tango Therapeutics is the single largest holding at $82.08 million (30.77%), while uniQure holds $46.70 million (17.51%). This level of concentration indicates significant conviction in these specific entities.
  • Core Positions: The third-largest holding, Revolution Medicines Inc (RVMD), accounts for 7.00% of the portfolio. Beyond the top three, position sizes drop significantly, generally ranging between 1% and 5%.
  • Long-Tail Exposure: The remainder of the portfolio consists of small-cap and micro-cap biotech stocks, many holding less than 1% of the portfolio weight. This structure suggests the fund uses its top holdings for core alpha generation while using smaller positions for high-risk/high-reward speculative exposure.
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
TNGX
TANGO THERAPEUTICS INC
$340M10.9M25.6%
02
RVMD
REVOLUTION MEDICINES INC
$94M500K7.1%
03
ABVX
ABIVAX SA
$81M605K6.1%
04
N90064101
UNIQURE NV
$69M1.5M5.2%
05
KOD
KODIAK SCIENCES INC
$58M1.5M4.3%
06
KYMR
KYMERA THERAPEUTICS INC
$49M429K3.7%
07
DFTX
DEFINIUM THERAPEUTICS INC
$47M999K3.5%
08
REPL
REPLIMUNE GROUP INC
$44M4.0M3.3%
09
CELC
CELCUITY INC
$44M417K3.3%
10
QTTB
Q32 BIO INC
$40M3.1M3.0%

Filing history

2026Q2Jun 30
$1.3B 74.3%
63 positionsView →
2026Q1Mar 31
$762M 66.7%
54 positionsView →
2025Q4Dec 31
$457M 45.6%
45 positionsView →
2025Q3Sep 30
$314M 57.9%
34 positionsView →
2025Q2Jun 30
$199M 40.2%
20 positionsLocked
2025Q1Mar 31
$332M 71.7%
28 positionsLocked
2024Q4Dec 31
$1.2B
60 positionsLocked